Back نالوكسون Arabic نالوکسان AZB Налоксон Bulgarian Naloxona Catalan Naloxon Czech Nalocson Welsh Naloxon Danish Naloxon German Ναλοξόνη Greek Naloxona Spanish

Naloxone

Not to be confused with Naltrexone or Naloxegol.

Naloxone
Clinical data
Trade namesNarcan, Evzio, Nyxoid, others
Other namesEN-1530; N-Allylnoroxymorphone; 17-Allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one, naloxone hydrochloride (USAN US)
AHFS/Drugs.comMonograph
MedlinePlusa612022
License data
Pregnancy
category
Routes of
administration		Nasal, intravenous, intramuscular
Drug classOpioid antagonist
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability2% (by mouth, 90% absorption but high first-pass metabolism)
43–54% (intranasally)
98% (intramuscular, subcutaneous)[12][13]
MetabolismLiver
Onset of action2 min (IVTooltip intravenous injection), 5 min (IMTooltip intramuscular injection)[13]
Elimination half-life1–1.5 h
Duration of action30–60 min[13]
ExcretionUrine, bile
Identifiers
  • (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-(prop-2-en-1-yl)-2,3,4,4a,5,6-hexahydro-1H-4,12-methano[1]benzofurano[3,2-e]isoquinolin-7(7aH)-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.697 Edit this at Wikidata
Chemical and physical data
FormulaC19H21NO4
Molar mass327.380 g·mol−1
3D model (JSmol)
  • O=C1[C@@H]2OC3=C(O)C=CC4=C3[C@@]2([C@]5(CC1)O)CCN(CC=C)[C@@H]5C4
  • InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1 checkY
  • Key:UZHSEJADLWPNLE-GRGSLBFTSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Naloxone is an opioid antagonist: a medication used to reverse or reduce the effects of opioids.[13] For example, it is used to restore breathing after an opioid overdose. It is also known as Narcan. [13] Effects begin within two minutes when given intravenously, five minutes when injected into a muscle,[13] and ten minutes as a nasal spray.[14] Naloxone blocks the effects of opioids for 30 to 90 minutes.[15]

Administration to opioid-dependent individuals may cause symptoms of opioid withdrawal, including restlessness, agitation, nausea, vomiting, a fast heart rate, and sweating.[13] To prevent this, small doses every few minutes can be given until the desired effect is reached.[13] In those with previous heart disease or taking medications that negatively affect the heart, further heart problems have occurred.[13] It appears to be safe in pregnancy, after having been given to a limited number of women.[16] Naloxone is a non-selective and competitive opioid receptor antagonist.[6][17] It reverses the depression of the central nervous system and respiratory system caused by opioids.[13]

Naloxone was patented in 1961 and approved for opioid overdose in the United States in 1971.[18][19] It is on the World Health Organization's List of Essential Medicines.[20]

  1. ^ "Naloxone Use During Pregnancy". Drugs.com. 2 September 2019. Archived from the original on 25 April 2020. Retrieved 13 May 2020.
  2. ^ Cite error: The named reference doi 10.5694/mja15.01181 was invoked but never defined (see the help page).
  3. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  4. ^ "Frequently Asked Questions: Access to naloxone in Canada (including Narcan Nasal Spray)". Health Canada. 6 July 2016. Archived from the original on 16 August 2021. Retrieved 16 August 2021.
  5. ^ "Naloxone 400 micrograms/ml solution for Injection/Infusion – Summary of Product Characteristics (SmPC)". (emc). 6 February 2019. Archived from the original on 4 August 2020. Retrieved 13 May 2020.
  6. ^ a b Cite error: The named reference Narcan FDA label was invoked but never defined (see the help page).
  7. ^ "Evzio- naloxone hydrochloride injection, solution". DailyMed. 1 February 2018. Archived from the original on 8 October 2020. Retrieved 5 October 2020.
  8. ^ "Zimhi- naloxone hydrochloride injection, solution". DailyMed. 29 September 2022. Archived from the original on 7 January 2023. Retrieved 7 January 2023.
  9. ^ Cite error: The named reference Kloxxado FDA label was invoked but never defined (see the help page).
  10. ^ "Narcan- naloxone hydrochloride nasal spray". DailyMed. 8 August 2023. Retrieved 5 September 2024.
  11. ^ "Rivive- naloxone hydrochloride spray". DailyMed. 10 January 2024. Retrieved 5 September 2024.
  12. ^ Ryan SA, Dunne RB (May 2018). "Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review". Pain Management. 8 (3): 231–245. doi:10.2217/pmt-2017-0060. PMID 29683378.
  13. ^ a b c d e f g h i j "Naloxone Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 2 January 2015. Retrieved 2 January 2015.
  14. ^ McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, et al. (March 2018). "Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study". Addiction. 113 (3): 484–493. doi:10.1111/add.14033. PMC 5836974. PMID 29143400.{{cite journal}}: CS1 maint: overridden setting (link)
  15. ^ "Naloxone DrugFacts". National Institute on Drug Abuse. 1 June 2021. Archived from the original on 6 January 2022. Retrieved 5 January 2022.
  16. ^ "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
  17. ^ Cite error: The named reference NHM-Naloxone pharmacology was invoked but never defined (see the help page).
  18. ^ Yardley W (14 December 2013). "Jack Fishman Dies at 83; Saved Many From Overdose". The New York Times. Archived from the original on 15 December 2013. Retrieved 6 July 2015.
  19. ^ US patent 3493657, Jack Fishman & Mozes Juda Lewenstein, "Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine", published 1970-02-03, issued 1970-02-03, assigned to Mozes Juda Lewenstein  Archived 7 December 2022 at the Wayback Machine
  20. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

Developed by StudentB